Cyclodextrin-based polymers for therapeutics delivery

A linear polymeric compound represented by Formula II:

• wherein
• P represents a monomer unit of a polymer;
• T, independently for each occurrence, represents a targeting ligand or a precursor thereof;
• L6, L7, L8, L9, and L10, independently for each occurrence, may be absent or represent a linker group;
• CD, independently for each occurrence, represents a cyclodextrin moiety or a derivative thereof;
• D, independently for each occurrence, represents a therapeutic agent or a prodrug form thereof;
• m, independently for each occurrence, represents an integer in the range of 1 to 10;
• o represents an integer in the range of 2 to about 30,000;
• and
• p, n, and q, independently for each occurrence, represent an integer in the range of 0 to 10,
• wherein CD and D are each present at least once in the compound and wherein at least one therapeutic agent or prodrug thereof is covalently attached to the polymer chain through attachments that are cleaved under biological conditions.

A linear polymeric compound represented by Formula III:

• wherein
• CD represents a cyclodextrin moiety, or derivative thereof;
• L4, L5, L6, and L7, independently for each occurrence, may be absent or represent a linker group;
• D and D′, independently for each occurrence, represent the same or different therapeutic agent or prodrugs thereof;
• T and T′, independently for each occurrence, represent the same or diff&rent targeting ligand or precursor thereof;
• f and y, independently for each occurrence, represent an integer in the range of 1 and 10;
• h represents an integer in the range of 2 to about 30,000;
• and
• g and z, independently for each occurrence, represent an integer in the range of 0 and 10,
• wherein at least one occurrence of g represents an integer greater than 0 and
• wherein a plurality of therapeutic agents or prodrugs thereof are covalently attached to the polymer chain through attachments that are cleaved under biological conditions.